Derek Gilchrist is Co-Founder, CEO and CSO of Causeway Therapeutics a Biopharmaceutical company focused on the development of novel therapies for the treatment of musculoskeletal diseases. Derek graduated from Glasgow University with a degree in Molecular Biology before going on to complete his PhD studies at Liverpool University. While working as a post-doctoral researcher, Derek made the key discovery that led to the development of TenoMiR, a promising therapy for the treatment of Tendinopathy. TenoMiR first-in-human trials are due to begin the end of 2019. Derek studied entrepreneurship at INSEAD and MIT.